The past two years have been challenging for Novo Nordisk (NVO +0.63%). The Denmark-based pharmaceutical company has dealt with worse-than-expected earnings, clinical-trial setbacks, and significant competition in its core therapeutic area that has eroded its market share.
And it seems like the bad news keeps on rolling in for the drugmaker. Recent regulatory changes in the U.S. have introduced yet another potential obstacle for Novo Nordisk.
When it rains, it pours. Let’s look into these developments and discuss whether it’s time to give up on the stock.
The price of Wegovy is going down
In 2022, President Joe Biden signed the Inflation Reduction Act into law. One of legislation’s…
